SGLT-2 inhibitors reduce mortality risk in HF with reduced EF but not in HF with preserved EF Medical Dialogues Editorial Team6 May 2022 8:45 AM ISTChina: In a new study published in Diabetes Research and Clinical Practice it was seen that in individuals with heart failure (HF) with reduced...
Coronary Revascularization Improves EF and reduces mortality and HF related hospitalization MD Bureau18 April 2022 11:04 PM ISTHeart failure is a major and growing public health issue worldwide. With the ageing population and advancements in medical and surgical treatments,...
Structural heart disease and premature ventricular contractions in recovery of exercise Dr. Nandita Mohan31 March 2022 4:00 PM ISTThe study evaluated echocardio graphic abnormalities (reduced left ventricular (LV) ejection fraction, valvular heart disease, LV dilatation, LV...
FDA approves Empagliflozin for heart failure despite contrary results Dr. Nandita Mohan3 March 2022 6:45 PM ISTTrials are being conducted to prevent cardiac death, The US Food and Drug Administration (FDA) has approved an expanded heart failure (HF) indication...
LIFE Trial: sacubitril/valsartan combination not effective to treat HF Dr. Nandita Mohan11 Feb 2022 7:01 PM ISTThe LIFE trial highlights that combination sacubitril/valsartan did not reduce N-terminal pro b-type natriuretic peptide (NT-proBNP) or clinical...
Emperor preserved trial: Empagliflozin effective to treat heart failure Dr. Nandita Mohan10 Feb 2022 7:30 PM IST The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic...
Intra Atrial shunt is inefficient in preventing heart failure Dr. Nandita Mohan7 Feb 2022 6:08 PM IST Surgical interventions are used timely in need of emergency to manage cardiac diseases. More than one-half of people with heart failure (HF)...
FDA approves empagliflozin for heart failure with reduced ejection fraction in adults Dr. Kamal Kant Kohli21 Aug 2021 7:15 AM ISTThe U.S. Food and Drug Administration has approved Jardiance (empagliflozin) to reduce the risk of cardiovascular mortality plus hospitalization for...
EMPEROR-Preserved confirms success of Empagliflozin in HFpEF Hina Zahid8 July 2021 9:45 AM ISTEmpagliflozin therapy with specific benefits in patients with heart failure and preserved ejection fraction (HFpEF) may finally be on its way as the...
Dapagliflozin is Effective in Both Men and Women with Heart Failure: JAMA MD Bureau5 April 2021 5:15 PM ISTDapagliflozin (Farxiga) is an SGLT2 inhibitor, previously approved by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes...
Intravenous iron reduced rehospitalization risk in people with heart failure Hina Zahid22 Feb 2021 8:15 AM ISTDALLAS - Patients who were hospitalized with acute heart failure and had iron deficiency were less likely to return to the hospital if given...
Vitamin D intake can improve ejection fraction in chronic heart failure: Study MD Bureau8 Dec 2020 10:15 AM ISTHeart failure is a pathophysiologic state in which the cardiac output is not able to supply the body with enough oxygen and nutrients. The prevalence...
